How efficient are Verve's sales expenditures now?

Verve Therapeutics appears to have inefficient sales expenditures as evidenced by the sales expense ratio and gross margin. The company's sales expense ratio, which is the operating expenses divided by the total revenue, is 100%. This indicates that all of the company's revenue is being spent on sales, leaving no profit margin. A sales expense ratio of this magnitude suggests that Verve is not generating any profit from its sales activities, which is a red flag for investors regarding the company's financial health and its ability to sustain itself.

|code|Ticker|Name|Date|Gross Profit Margin|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|VERV|VERV.O|Verve Therapeutics|2024 Q1|100||185|
|VERV|VERV.O|Verve Therapeutics|2024 Q2|100||185|
|VERV|VERV.O|Verve Therapeutics|2024 Q3|100||185|
|VERV|VERV.O|Verve Therapeutics|2024 Q4|100||185|